Alex J Eustace
Dublin City University
61 Papers
93 Citations
Alex J Eustace is an academic researcher from Dublin City University. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 14, co-authored 45 publications. Previous affiliations of Alex J Eustace include Royal College of Surgeons in Ireland & Beaumont Hospital.
Chat about Author
Papers
In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies.
Martina McDermott,Alex J Eustace,Steven Busschots,Laura Breen,John Crown,Martin Clynes,Norma O'Donovan,Britta K. Stordal +7 more
TL;DR: Key decisions to be made prior to starting resistant cell line development are discussed; the choice of parent cell line, dose of selecting agent, treatment interval, and optimizing the dose of drug for theparent cell line.
HER2-family signalling mechanisms, clinical implications and targeting in breast cancer
Naomi Elster,Denis M. Collins,Sinead Toomey,John Crown,Alex J Eustace,Bryan T. Hennessy,Bryan T. Hennessy +6 more
TL;DR: With the rapidly expanding understanding of HER2 signalling mechanisms along with the repertoire of HER family and other targeted therapies, it is likely that the near future holds further dramatic improvements to the prognosis of women with HER2-positive BC.
85
Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer
Denis M. Collins,Stephen F. Madden,N. Gaynor,Dalal Alsultan,Dalal Alsultan,Marion Le Gal,Alex J Eustace,Kathy Gately,Clare Hughes,Anthony Davies,Thamir Mahgoub,Jo Ballot,Sinead Toomey,Darran P. O'Connor,William M. Gallagher,Frankie A. Holmes,Virginia Espina,Lance A. Liotta,Bryan T. Hennessy,Bryan T. Hennessy,Kenneth J. O'Byrne,Max Hasmann,Birgit Bossenmaier,Norma O'Donovan,John Crown +24 more
TL;DR: TKIs differentially alter tumor cell phenotype which can impact NK cell–mediated response to coadministered antibody therapies, and mAb-induced ADCC response is relevant when rationalizing combinations for clinical investigation.
A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib
Naomi Elster,Mattia Cremona,Carys Morgan,Sinead Toomey,Aoife Carr,Anthony O'Grady,Bryan T. Hennessy,Alex J Eustace +7 more
TL;DR: The combination of HER2-targeted therapies and BAY 80-6946 inhibited growth more effectively than either therapy used alone (with clear synergism in many cases), and can restore sensitivity totrastuzumab and lapatinib in cells with acquired resistance to either trastuzuab and/or lapatin ib.
45
Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.
Brigid C. Browne,Alex J Eustace,Susan Kennedy,Neil A. O'Brien,Kasper Pedersen,Martina McDermott,Annemarie Larkin,Jo Ballot,Thamir Mahgoub,Francesco Sclafani,Stephen F. Madden,John Kennedy,Michael J. Duffy,John Crown,Norma O'Donovan +14 more
TL;DR: Evidence is provided that co-targeting HER2 and IGF1R may be beneficial in some HER2-amplified breast cancers, and the combination of trastuzumab with IGF1r tyrosine kinase inhibitors (TKIs) in a panel of Her2-positive breast cancer cell lines.